{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:38:40Z","timestamp":1774535920502,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T00:00:00Z","timestamp":1628380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T00:00:00Z","timestamp":1628380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Atherosclerotic cardiovascular disease (ASCVD) is a major cause of death worldwide. A large number of deaths due to ASCVD occurs among people with diabetes mellitus (DM). One of the important modifiable risk factors associated with ASCVD is dyslipidaemia and its prevalence is not known in central South Africa (SA). This study aimed to determine the pattern and prevalence of dyslipidaemia among type 2 diabetes mellitus (T2DM) patients on lipid-lowering therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This descriptive, retrospective study of patients\u2019 records was conducted at Universitas Academic Hospital in Bloemfontein, SA. The study population included 143 consecutive T2DM patients of any age that attended the Diabetes Clinic from 1 January to 31 March 2019. The patients had to be on lipid-lowering therapy for a minimum duration of 3 months. Data were sourced from the clinic files and included the patient\u2019s lipid profile, anthropometric and demographic data. Dyslipidaemia was defined using the 2018 SA dyslipidaemia guidelines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age of the participants was 63 years (interquartile range [IQR] 52\u201371 years). The majority of the participants were female (<jats:italic>n<\/jats:italic>\u2009=\u200992; 64.3\u2009%). The median duration since the DM diagnosis was 18 years (IQR 13\u201323 years). The prevalence of dyslipidaemia was 86.7\u2009% (<jats:italic>n<\/jats:italic>\u2009=\u2009124). Combined dyslipidaemia, namely either triglycerides (TG)\u2009+\u2009low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL)\u2009+\u2009TG or HDL\u2009+\u2009LDL, was the most common pattern (<jats:italic>n<\/jats:italic>\u2009=\u200951; 42.5\u2009%) largely due to raised TG\u2009+\u2009LDL contributing 37.2\u2009% (<jats:italic>n<\/jats:italic>\u2009=\u200919) to this pattern. The second and third most common patterns were isolated (either LDL, HDL or TG) and mixed dyslipidaemia (TG\u2009+\u2009HDL\u2009+\u2009LDL) at 40.8\u2009% (<jats:italic>n<\/jats:italic>\u2009=\u200949) and 16.7\u2009% (<jats:italic>n<\/jats:italic>\u2009=\u200920), respectively. The most frequent lipid abnormality (<jats:italic>n<\/jats:italic>\u2009=\u200984; 70.0\u2009%) was LDL of \u2265\u20091.8 mmol\/L. Of the 140 participants on statin therapy, only 5\u2009% were on high-intensity therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A high prevalence of dyslipidaemia among DM patients was observed, despite the use of lipid-lowering therapy in this small observational study. Our findings highlight the need to better educate healthcare providers regarding the intensification of lipid-lowering therapy, along with improved strategies to address poor glycaemic control and other modifiable lifestyle factors.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12902-021-00813-7","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T04:12:41Z","timestamp":1628395961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Dyslipidaemia pattern and prevalence among type 2 diabetes mellitus patients on lipid-lowering therapy at a tertiary hospital in central South Africa"],"prefix":"10.1186","volume":"21","author":[{"given":"Lebohang","family":"Pitso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thabiso Rafaki Petrus","family":"Mofokeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riette","family":"Nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,8]]},"reference":[{"key":"813_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels: International Diabetes Federation; 2019. Available at: http:\/\/www.idf.org\/aboutdiabetes\/what-is-diabetes\/facts-figures.html"},{"key":"813_CR2","unstructured":"Blom DJ. Dyslipidaemia in type 2 diabetes: review. S Afr J Diabetes Vasc Dis. 2013;10(2):48\u201350. Available at: http:\/\/www.diabetesjournal.co.za\/onlinejournal\/vol10\/vol10_issue2\/files\/assets\/basic-html\/index.htm."},{"issue":"1","key":"813_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s42000-018-0014-8","volume":"17","author":"VG Athyros","year":"2018","unstructured":"Athyros VG, Doumas M, Imprialos KP, Stavropoulos K, Georgianou E, Katsimardou A, et al. Diabetes and lipid metabolism. Hormones (Athens). 2018;17(1):61\u20137. https:\/\/doi.org\/10.1007\/s42000-018-0014-8","journal-title":"Hormones (Athens)"},{"issue":"1","key":"813_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"issue":"2","key":"813_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s13300-016-0167-x","volume":"7","author":"JD Schofield","year":"2016","unstructured":"Schofield JD, Liu Y, Rao-Balakrishna P, Malik RA, Soran H. Diabetes dyslipidemia. Diabetes Ther. 2016;7(2):203\u201319. https:\/\/doi.org\/10.1007\/s13300-016-0167-x","journal-title":"Diabetes Ther"},{"issue":"32","key":"813_CR6","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144","journal-title":"Eur Heart J"},{"issue":"16","key":"813_CR7","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMra1806939","volume":"381","author":"ED Michos","year":"2019","unstructured":"Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. 2019;381(16):1557\u201367. https:\/\/doi.org\/10.1056\/NEJMra1806939","journal-title":"N Engl J Med"},{"issue":"4","key":"813_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4239\/wjd.v5.i4.444","volume":"5","author":"I Mart\u00edn-Tim\u00f3n","year":"2014","unstructured":"Mart\u00edn-Tim\u00f3n I, Sevillano-Collantes C, Segura-Galindo A, Del Ca\u00f1izo-G\u00f3mez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5(4):444\u201370. https:\/\/doi.org\/10.4239\/wjd.v5.i4.444","journal-title":"World J Diabetes"},{"issue":"1","key":"813_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12872-019-1213-1","volume":"19","author":"S Kamil","year":"2019","unstructured":"Kamil S, Sehested TSG, Carlson N, Houlind K, Lassen JF, Bang CN, et al. Diabetes and risk of peripheral artery disease in patients undergoing first-time coronary angiography between 2000 and 2012 \u2013 a nationwide study. BMC Cardiovasc Disord. 2019;19(1):234. https:\/\/doi.org\/10.1186\/s12872-019-1213-1","journal-title":"BMC Cardiovasc Disord"},{"issue":"8","key":"813_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.cardfail.2019.05.007","volume":"25","author":"SM Dunlay","year":"2019","unstructured":"Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, et al. Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and Heart Failure Society of America. J Card Fail. 2019;25(8):584\u2013619. https:\/\/doi.org\/10.1016\/j.cardfail.2019.05.007","journal-title":"J Card Fail"},{"issue":"1","key":"813_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","volume":"124","author":"HC Kenny","year":"2019","unstructured":"Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus: impact of glucose-lowering agents, heart failure therapies, and novel therapeutic strategies. Circ Res. 2019;124(1):121\u201341. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.311371","journal-title":"Circ Res"},{"issue":"14","key":"813_CR12","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/eurheartj\/ehx566","volume":"39","author":"KC Koskinas","year":"2018","unstructured":"Koskinas KC, Siontis GCM, Piccolo R, Mavridis D, R\u00e4ber L, Mach F, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018;39(14):1172\u201380. https:\/\/doi.org\/10.1093\/eurheartj\/ehx566","journal-title":"Eur Heart J"},{"issue":"10059","key":"813_CR13","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(16)31357-5","journal-title":"Lancet"},{"issue":"1","key":"813_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15277\/bjd.2018.161","volume":"18","author":"F Naeem","year":"2018","unstructured":"Naeem F, McKay G, Fisher M. Cardiovascular outcomes trials with statins in diabetes. Br J Diabetes. 2018;18(1):7\u201313. https:\/\/doi.org\/10.15277\/bjd.2018.161","journal-title":"Br J Diabetes"},{"issue":"19","key":"813_CR15","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.2015.15629","volume":"316","author":"R Chou","year":"2016","unstructured":"Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316(19):2008\u201324. https:\/\/doi.org\/10.1001\/jama.2015.15629","journal-title":"JAMA"},{"issue":"11","key":"813_CR16","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000678","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596\u2013e646. https:\/\/doi.org\/10.1161\/CIR.0000000000000678","journal-title":"Circulation"},{"issue":"25","key":"813_CR17","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, Wjite JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489","journal-title":"N Engl J Med"},{"key":"813_CR18","doi-asserted-by":"crossref","unstructured":"Klug E, Raal FJ, Marais AD, Smuts CM, Schamroth C, Jankelow D, et al. South African dyslipidaemia guideline consensus statement: 2018 update. A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). S Afr Med J. 2018;108(11b):973\u20131000. Available at: http:\/\/www.samj.org.za\/index.php\/samj\/article\/view\/12479\/8686","DOI":"10.7196\/SAMJ.2018.v108i11.13383"},{"key":"813_CR19","unstructured":"Amod A. SEMDSA 2017 guidelines for the management of type 2 diabetes mellitus. J Eendocinol Metab Diabetes S Afr. 2017;22(1 Suppl 1):S1\u2013196. Available at: http:\/\/www.jemdsa.co.za\/index.php\/JEMDSA\/article\/view\/647"},{"issue":"1","key":"813_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12872-017-0591-5","volume":"17","author":"JP Halcox","year":"2017","unstructured":"Halcox JP, Banegas JR, Roy C, Dallongeville J, De Backer G, Guallar E, et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc Disord. 2017;17(1):160. https:\/\/doi.org\/10.1186\/s12872-017-0591-5","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"813_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5830\/CVJA-2018-054","volume":"30","author":"DJ Blom","year":"2019","unstructured":"Blom DJ, Raal F, Amod A, Naidoo P, Lai Y. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS). Cardiovasc J Afr. 2019;30(1):15\u201323. https:\/\/doi.org\/10.5830\/CVJA-2018-054","journal-title":"Cardiovasc J Afr"},{"issue":"6","key":"813_CR22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5830\/CVJA-2014-062","volume":"25","author":"YK Seedat","year":"2014","unstructured":"Seedat YK, Rayner BL, Veriava Y. South African hypertension practice guideline 2014. Cardiovasc J Afr. 2014;25(6):288\u201394. https:\/\/doi.org\/10.5830\/CVJA-2014-062","journal-title":"Cardiovasc J Afr"},{"key":"813_CR23","unstructured":"World Health Organization. Obesity: preventing and managing the global epidemic: report of a WHO consultation. Geneva: WHO; 2000. Available at: https:\/\/apps.who.int\/iris\/handle\/10665\/42330"},{"issue":"9","key":"813_CR24","doi-asserted-by":"publisher","first-page":"e998","DOI":"10.1016\/S2214-109X(18)30275-4","volume":"6","author":"JJ Noubiap","year":"2018","unstructured":"Noubiap JJ, Bigna JJ, Nansseu JR, Nyaga UF, Balti EV, Echouffo-Tcheugui JB, et al. Prevalence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis. Lancet Glob Health. 2018;6(9):e998\u2013e1007. https:\/\/doi.org\/10.1016\/S2214-109X(18)30275-4","journal-title":"Lancet Glob Health"},{"key":"813_CR25","doi-asserted-by":"crossref","unstructured":"Daya R, Bayat Z, Raal F. Prevalence and pattern of dyslipidaemia in type 2 diabetes mellitus patients at a tertiary care hospital. J Endocrinol Metab Diabetes S Afr. 2017;22(3):31\u20135. Available at: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/16089677.2017.1360064#.VQcjlpWJhgU","DOI":"10.1080\/16089677.2017.1360064"},{"key":"813_CR26","doi-asserted-by":"crossref","unstructured":"Naidoo S, Raal F. Pattern of dyslipidaemia in relation to statin use in patients with type 2 diabetes mellitus attending a tertiary care hospital. J Endocrinol Metab Diabetes S Afr. 2020;25(1):6\u201311. Available at: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/16089677.2019.1686869","DOI":"10.1080\/16089677.2019.1686869"},{"issue":"12","key":"813_CR27","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/ijcp.12238","volume":"67","author":"K Jameson","year":"2013","unstructured":"Jameson K, Amber V, D\u2019Oca K, Mills D, Giles A, Ambegaonkar B. Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care \u2013 a retrospective database study. Int J Clin Pract. 2013;67(12):1228\u201337. https:\/\/doi.org\/10.1111\/ijcp.12238","journal-title":"Int J Clin Pract"},{"issue":"2","key":"813_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.atherosclerosis.2014.05.916","volume":"235","author":"S Zhao","year":"2014","unstructured":"Zhao S, Wang Y, Mu Y, Yu B, Ye P, Yan X, et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS). Atherosclerosis. 2014;235(2):463\u20139. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.05.916","journal-title":"Atherosclerosis"},{"issue":"10","key":"813_CR29","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/2047487318777079","volume":"25","author":"N Danchin","year":"2018","unstructured":"Danchin N, Almahmeed W, Al-Rasadi K, Azuri J, Berrah A, Cuneo CA, et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: the International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol. 2018;25(10):1087\u201394. https:\/\/doi.org\/10.1177\/2047487318777079","journal-title":"Eur J Prev Cardiol"},{"key":"813_CR30","unstructured":"Mahajan R, Koley S. Association of HbA1c with Lipid profiles in patients with type 2 diabetes mellitus. Int J Biomed Res. 2016;7(3):139\u201343. Available at: https:\/\/ssjournals.com\/index.php\/ijbr\/article\/view\/3098"},{"issue":"1","key":"813_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/XCE.0000000000000120","volume":"6","author":"HJ Warraich","year":"2017","unstructured":"Warraich HJ, Rana JS. Dyslipidemia in diabetes mellitus and cardiovascular disease. Cardiovasc Endocrinol. 2017;6(1):27\u201332. https:\/\/doi.org\/10.1097\/XCE.0000000000000120","journal-title":"Cardiovasc Endocrinol"},{"issue":"5","key":"813_CR32","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4239\/wjd.v10.i5.280","volume":"10","author":"I Jialal","year":"2019","unstructured":"Jialal I, Singh G. Management of diabetic dyslipidemia: an update. World J Diabetes. 2019;10(5):280\u201390. https:\/\/doi.org\/10.4239\/wjd.v10.i5.280","journal-title":"World J Diabetes"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00813-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-021-00813-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00813-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T22:06:11Z","timestamp":1673042771000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-021-00813-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,8]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["813"],"URL":"https:\/\/doi.org\/10.1186\/s12902-021-00813-7","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,8]]},"assertion":[{"value":"15 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Health Sciences Research Ethics Committee (HSREC) of the University of the Free State with ethical clearance number UFS-HSD2019\/0869\/2506. Permission to use hospital data was granted by the Department of Health, Free State Province, South Africa.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Due to the retrospective nature of the study, the requirement to obtain informed consent was waived by the Health Sciences Research Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"159"}}